PerspectiveCancer Immunotherapy

Clinical implications of tumor-intrinsic mechanisms regulating PD-L1

See allHide authors and affiliations

Science Translational Medicine  06 Feb 2019:
Vol. 11, Issue 478, eaav4810
DOI: 10.1126/scitranslmed.aav4810

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

Treatment with immune checkpoint inhibitors targeting programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) is effective in many cancer types. Tumors harboring specific mutations modulate antitumor immune responses through the PD-1/PD-L1 axis, and this should be taken into account when designing rational combinatory treatments.

View Full Text